Ondine Biomedical Inc.
OBI.L · LSE
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -9.58% | -21.98% | -17.85% | -20.58% |
| EV / EBITDA | -6.16 | -7.50 | -4.22 | -4.78 |
| Quality | ||||
| ROIC | -92.47% | -1,231.59% | -255.29% | -157.14% |
| Gross Margin | 44.45% | 29.92% | 22.71% | -10.05% |
| Cash Conversion Ratio | 0.72 | 0.91 | 0.82 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 22.28% | 26.59% | 23.33% | 15.25% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 1.55 | 0.21 | 0.38 | 0.48 |
| Interest Coverage | -464.58 | -355.93 | -376.46 | -401.51 |
| Efficiency | ||||
| Inventory Turnover | 0.29 | 0.47 | 0.56 | 0.44 |
| Cash Conversion Cycle | -7.05 | -63.71 | -6.84 | 161.92 |